



The COVID-19 Mass Vaccination Programme

Situation

- Delivered milestone 1 (groups 1 to 4) by required date – 14th February 2021
- Focus on 2nd doses due to significantly reduced first dose supplies (Pfizer and AZ) from 15th Feb to 7th March
- Significant 1st dose delivery of AZ W/c 8th March with aim to completing group 5, progressing group 6 (ever increasing group) and starting group 7
- Groups 5 & 6 delivered by primary care and 7,8 & 9 through the MVCs
- Planning for phase 2/group 10/rest of the adult population by end of July 2021 (milestone 3)
- Conversations about beyond phase 2 and potential for a booster at the same time as the flu jab and uncertainty around suitable MVC venues

Risks and Mitigation


- Corporate risk:- There is a risk to the Health Board's reputation should there be a perception that the HB does not have a coherent and/or deliverable plan for the COVID-19 Vaccination Programme
- Operational risks:- numerous, variable and ever-changing managed through vaccination Bronze Group (chaired by Bethan Lewis and vice chair Jo McCarthy) and reported through to Silver/tactical meeting
- Key elements:
 - Great political, public & media interest
 - Uptake is incredible (high 90's%)
 - High and large scale expectations
 - Ever-changing policy requirements
 - Variable vaccine supplies
 - Hunger for the detail

Describing the risk: COVID-19 vaccination programme

Date Risk Identified:	Dec-20	Executive Director Owner:	Jervis, Ros	Date of Review:	Feb-21
Strategic Objective:	Delivery of the Quarter 3/4 Operating Plan	Lead Committee:	People, Planning and Performance Assurance Committee	Date of Next Review:	Apr-21

Risk ID:	1030	Principal Risk Description:	There is a risk to the Health Board's reputation should there be a perception that the HB does not have a coherent and/or deliverable plan for the COVID-19 Vaccination Programme. This is caused by significant and ever changing vaccine policy requirements, delivery parameters such as workforce requirements and vaccination supplies in overall doses and vaccine type. This could lead to an impact/affect on a reduction in stakeholder confidence, increased scrutiny from the local community, the media, regulators and WG increasing pressure to deliver on all aspects of the programme, at pace, whilst competing with other Health Board priorities and operational challenges.
-----------------	------	------------------------------------	---

Risk Rating:(Likelihood x Impact)	
Domain:	Adverse publicity/reputation
Inherent Risk Score (L x I):	3x4=12
Current Risk Score (L x I):	2x4=8
Target Risk Score (L x I):	2x4=8
Tolerable Risk:	8



Does this risk link to any Directorate (operational) risks?

Trend:

Rationale for CURRENT Risk Score:
 The Board have approved the Mass Vaccination Delivery Plan, which addressed many of the previously articulated gaps in control. The plan is progressing at pace and is being managed by the Bronze Vaccination Delivery Group and overseen by the Silver Tactical Group. There remains changing advice and guidance as the programme commences and knowledge of these novel vaccines evolves.

Rationale for TARGET Risk Score:
 As the programme delivery embeds, and initial uncertainties settle and knowledge/understanding of each vaccine and their individual characteristics improve. Expectations of individuals within our workforce and our communities will be better understood and supported over time.

Mitigation

Assurance

ASSURANCE MAP				Control RAG Rating (what the assurance is telling you about your controls)	Latest Papers (Committee & date)	Gaps in ASSURANCES					
Performance Indicators	Sources of ASSURANCE	Type of Assurance (1st, 2nd, 3rd)	Required Assurance █ Current Level			Identified Gaps in Assurance:	How are the Gaps in ASSURANCE will be addressed Further action necessary to address the gaps	By Who	By When	Progress	
Regular reporting of progress and position to National Covid Vaccine Board (CVB).	Regular reporting into Hywel Dda Tactical (Silver) Group	2nd	█	█		None identified.	To complete Internal Audit review of Hywel Dda Vaccination Programme	Jervis, Ros	30/04/2021	Added to Internal Plan 2020/21. Meeting held with Director of Public Health.	
	Regular updates to Executive Team and Integrated Executive Group (RPB)	2nd	█								
	Regular reporting into Dyfed Powys Local Resilience Forum	2nd	█								
	Core member of, and regular reporting to (including daily sitreps), the National Covid Vaccine Delivery Board (CVB)	2nd	█								

Recommendation

For QSEAC (COVID-19) to take an assurance from the presentation provided.